* any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study. * subjects with evidence of critical covid 19 illness, defined by at least 1 of the following: respiratory failure; shock (defined by systolic blood pressure \<90 mm hg, or diastolic blood pressure \<60 mm hg, or requiring vasopressors); or multi-organ dysfunction/failure. * subjects requiring extracorporeal membrane oxygenation (ecmo). * stage 4 severe chronic kidney disease or requiring dialysis (ie, estimated glomerular filtration rate(egfr) ml/min/1.73 m2 \< 30). * pregnant or breast feeding. * anticipated transfer to another hospital which is not a study site within 72 hours. * allergy to any study medication. * use of anticancer, antitransplant rejection, or immunomodulatory biological drug or kinase inhibitor (eg, tocilizumab, sarilumab) or janus kinase inhibitors (within 30 days of enrollment or 5 times the half-life \[whichever is longer\]). * chronic glucocorticosteroid use equivalent to daily oral prednisone \>10 mg per day (10 mg oral prednisone every other day is allowed). * live (live-attenuated) vaccines are not permitted within 2 weeks prior to randomization or during the study treatment and safety follow-up periods. * subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer. * total bilirubin (tbl) \>2 × upper limit of normal (uln), or alanine aminotransferase (alt) \>5 × uln, or aspartate aminotransferase (ast) \>5 × uln, or alkaline phosphatase \>5 × uln. * platelet \<50×109/l, or hemoglobin \<60g/l. * glomerular filtration rate \<30 milliliter(ml)/min/1.73 m2, or serum creatinine increased by 0.5 mg/dl within 7 days, or oliguria (\<400 ml/24 hour), or anuria (\<100 ml/24 hour). * any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study.

* any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study. * subjects with evidence of critical covid 19 illness, defined by at least 1 of the following: respiratory failure; shock (defined by systolic blood pressure \<90 mm hg, or diastolic blood pressure \<60 mm hg, or requiring vasopressors); or multi-organ dysfunction/failure. * subjects requiring extracorporeal membrane oxygenation (ecmo). * stage 4 severe chronic kidney disease or requiring dialysis (ie, estimated glomerular filtration rate(egfr) ml/min/1.73 m2 \< 30). * pregnant or breast feeding. * anticipated transfer to another hospital which is not a study site within 72 hours. * allergy to any study medication. * use of anticancer, antitransplant rejection, or immunomodulatory biological drug or kinase inhibitor (eg, tocilizumab, sarilumab) or janus kinase inhibitors (within 30 days of enrollment or 5 times the half-life \[whichever is longer\]). * chronic glucocorticosteroid use equivalent to daily oral prednisone \>10 mg per day (10 mg oral prednisone every other day is allowed). * live (live-attenuated) vaccines are not permitted within 2 weeks prior to randomization or during the study treatment and safety follow-up periods. * subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer. * total bilirubin (tbl) \>2 × upper limit of normal (uln), or alanine aminotransferase (alt) \>5 × uln, or aspartate aminotransferase (ast) \>5 × uln, or alkaline phosphatase \>5 × uln. * platelet \<50×109/l, or hemoglobin \<60g/l. * glomerular filtration rate \<30 milliliter(ml)/min/1.73 m2, or serum creatinine increased by 0.5 mg/dl within 7 days, or oliguria (\<400 ml/24 hour), or anuria (\<100 ml/24 hour). * any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study.

- any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study. - subjects with evidence of critical covid 19 illness, defined by at least 1 of the following: respiratory failure; shock (defined by systolic blood pressure <90 mm hg, or diastolic blood pressure <60 mm hg, or requiring vasopressors); or multi-organ dysfunction/failure. - subjects requiring extracorporeal membrane oxygenation (ecmo). - stage 4 severe chronic kidney disease or requiring dialysis (ie, estimated glomerular filtration rate(egfr) ml/min/1.73 m2 < 30). - pregnant or breast feeding. - anticipated transfer to another hospital which is not a study site within 72 hours. - allergy to any study medication. - use of anticancer, antitransplant rejection, or immunomodulatory biological drug or kinase inhibitor (eg, tocilizumab, sarilumab) or janus kinase inhibitors (within 30 days of enrollment or 5 times the half-life [whichever is longer]). - chronic glucocorticosteroid use equivalent to daily oral prednisone >10 mg per day (10 mg oral prednisone every other day is allowed). - live (live-attenuated) vaccines are not permitted within 2 weeks prior to randomization or during the study treatment and safety follow-up periods. - subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer. - total bilirubin (tbl) >2 × upper limit of normal (uln), or alanine aminotransferase (alt) >5 × uln, or aspartate aminotransferase (ast) >5 × uln, or alkaline phosphatase >5 × uln. - platelet <50×109/l, or hemoglobin <60g/l. - glomerular filtration rate <30 milliliter(ml)/min/1.73 m2, or serum creatinine increased by 0.5 mg/dl within 7 days, or oliguria (<400 ml/24 hour), or anuria (<100 ml/24 hour). - any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study.

- any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study. - subjects with evidence of critical covid 19 illness, defined by at least 1 of the following: respiratory failure; shock (defined by systolic blood pressure <90 mm hg, or diastolic blood pressure <60 mm hg, or requiring vasopressors); or multi-organ dysfunction/failure. - subjects requiring extracorporeal membrane oxygenation (ecmo). - stage 4 severe chronic kidney disease or requiring dialysis (ie, estimated glomerular filtration rate(egfr) ml/min/1.73 m2 < 30). - pregnant or breast feeding. - anticipated transfer to another hospital which is not a study site within 72 hours. - allergy to any study medication. - use of anticancer, antitransplant rejection, or immunomodulatory biological drug or kinase inhibitor (eg, tocilizumab, sarilumab) or janus kinase inhibitors (within 30 days of enrollment or 5 times the half-life [whichever is longer]). - chronic glucocorticosteroid use equivalent to daily oral prednisone >10 mg per day (10 mg oral prednisone every other day is allowed). - live (live-attenuated) vaccines are not permitted within 2 weeks prior to randomization or during the study treatment and safety follow-up periods. - subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer. - total bilirubin (tbl) >2 × upper limit of normal (uln), or alanine aminotransferase (alt) >5 × uln, or aspartate aminotransferase (ast) >5 × uln, or alkaline phosphatase >5 × uln. - platelet <50×109/l, or hemoglobin <60g/l. - glomerular filtration rate <30 milliliter(ml)/min/1.73 m2, or serum creatinine increased by 0.5 mg/dl within 7 days, or oliguria (<400 ml/24 hour), or anuria (<100 ml/24 hour). - any physical examination findings, laboratory abnormality, and/or history of any illness, that in the study investigator's judgment, could jeopardize the safety of the subject by their participation in the study.